At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,258 enrolled
Drug / intervention
20-valent pneumococcal conjugate vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE GIVEN AS A SERIES OF 2 INFANT DOSES AND 1 TODDLER DOSE IN HEALTHY INFANTS
In Brief
A Phase 3 clinical trial evaluating 20-valent pneumococcal conjugate vaccine and 13-valent pneumococcal conjugate vaccine for Pneumococcal Disease. Completed, enrolled 1,258 participants across 66 sites in 12 countries.
Detailed Summary
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumococcal Disease
CountriesAustralia, Belgium, Czechia, Denmark, Estonia, Finland, Italy, Netherlands, Norway, Poland, Russia, Slovakia
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
Enrollment StartSep 2020
First PostedSep 2020
Primary CompletionApr 2022
Study CompletionFeb 2023
TodayJul 2026
First PostedSep 14, 2020
Enrollment StartSep 9, 2020
Primary CompletionApr 22, 2022
Study CompletionFeb 18, 2023
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 5.8 years ago
Interventions
20-valent pneumococcal conjugate vaccinebiological
20-valent pneumococcal conjugate vaccine
13-valent pneumococcal conjugate vaccinebiological
13-valent pneumococcal conjugate vaccine